Clinical trials: Neoplasm, Brain
Brain and Central Nervous System Tumors
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00275067
- Testing
- arsenic trioxide, temozolomide, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Primary Brain Tumor, Caregiver Burden
The Effect of Home Care Planned According to Orem in Patients With Primary Brain Tumor and Their Caregivers
This study was conducted to evaluate the effect of home care planned according to Orem on self-care agency and care burden in brain tumor patients and their caregivers.
- Conditions
- Primary Brain Tumor, Caregiver Burden, Self Care
- Trial name
- NCT05328739
- Testing
- home care
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
Brain Metastases
Improving Therapeutic Ratio With Hypo Fractionated Stereotactic Radiotherapy for Brain Metastases
Randomized phase II trial. The study aims to investigate a different and potentially safer radio therapeutic treatment method for brain metastases.
- Trial name
- SAFESTEREO (NCT05346367)
- Testing
- SRT, fSRT
- Where
- Netherlands
- Volunteers
- 130 people
- Sponsor
- Haaglanden Medical Centre
Brain and Central Nervous System Tumors, Melanoma
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
RATIONALE: Drugs used in chemotherapy, temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Melanoma, Solid Tumor
- Trial name
- NCT00512798
- Testing
- PS-341 (VELCADE), temozolomide, immunoenzyme technique
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Brain Metastases
Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases
Brain metastases are the most common intracranial tumors in adults. Whole-brain radiation therapy (WBI) increases the median survival of patients with brain metastases up to 3-6 months, but WBI can lead to the decline of…
- Trial name
- SMART-Brain (NCT03414944)
- Testing
- SMART-Brain
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, mannitol, and sodium thiosulfate, and to see how well they work in treating patients with central nervous system…
- Conditions
- Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Germ Cell Tumor, Medulloblastoma
- Trial name
- NCT00983398
- Testing
- Carboplatin, Mannitol, Melphalan
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Cancer
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
This study will construct tissue microarrays (TMAs) pertaining to childhood cancer. TMA technology is a recently developed one that allows for evaluating hundreds of tissue samples simultaneously on the DNA, RNA, and protein…
- Trial name
- NCT00340522
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Intracranial Tumor
Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation
With the appliance of the in-vivo microscopy after Fluorescein staining, the investigators hypothesize that the preliminary in-vivo histopathological diagnostic accuracy is not inferior to conventional frozen section analysis…
- Trial name
- INVIVO (NCT04597801)
- Testing
- Alcon
- Where
- 3 sites in Germany
- Volunteers
- 210 people
- Sponsor
- Technical University of Munich
Amyloid, Amyloidosis
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
- Conditions
- Amyloid, Amyloidosis, AL Amyloidosis
- Trial name
- STARR (NCT04984330)
- Testing
- Selinexor, Dexamethasone
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Epilepsy, Tumor
Recording High Frequency Oscillations in Patients With Tumors and Epilepsy
The investigators want to characterize high-frequency oscillations (HFOs) in intracranial recordings, which may occur as markers of epileptogenic tissue and also under physiological stimulation.
- Trial name
- HFO (NCT02320136)
- Testing
- cognitive testing
- Volunteers
- 120 people
- Sponsor
- University of Zurich
Brain Tumor, Cerebrovascular Disorders
The Neuroprotective Effects of Dexmedetomidine During Brain Surgery
Dexmedetomidine (DEX) is a Alpha-2 specific agonist, is a common ICU sedation medication. In brain tumor resection craniotomy, it is proven to be effective in improving postoperative hypertension and tachycardia, mitigates…
- Trial name
- NCT02878707
- Testing
- Dexmedetomidine
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Brain and Central Nervous System Tumors
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00482677
- Testing
- temozolomide, DNA methylation analysis, quality-of-life assessment
- Where
- 22 sites in Canada, Germany and 2 more
- Volunteers
- 562 people
- Sponsor
- Canadian Cancer Trials Group
Glioblastoma Multiforme, Cognition Disorders
Bevacizumab and Lomustine for Recurrent GBM
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Glioblastoma Multiforme, Cognition Disorders, Disability Evaluation
- Trial name
- NCT01290939
- Testing
- bevacizumab, lomustine, DNA methylation analysis
- Where
- 2 sites in Netherlands
- Volunteers
- 592 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238277
- Testing
- temozolomide, adjuvant therapy, chemotherapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ARDS (Moderate or Severe)
Prone Positioning in ARDS: Predicting Neurological Complications Via Cerebral Hemodynamics
Prone Positioning in ARDS: Predicting Neurological Complications via Cerebral Hemodynamics
- Trial name
- PRONEBRAINAR (NCT06967285)
- Testing
- Prone ventilation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sichuan Provincial People's Hospital
Small Cell Lung Cancer, Brain Metastases, Adult
Tarlatamab for SCLC Brain Metastases
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
- Trial name
- T-BRAIN (NCT07402343)
- Testing
- Tarlatamab
- Where
- 4 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- Maastricht University Medical Center
Prostate Cancer, Renal Cancer
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
This is a parallel group, single institution, prospective clinical study. The purpose of this study is to assess whether the Jawbone Up 24, a consumer based accelerometer, can be a feasible tool to study physical activity in…
- Conditions
- Prostate Cancer, Renal Cancer, Brain Cancer, ALS
- Trial name
- NCT02457715
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
This phase I trial studies the safety and side effects of a new positron emission tomography (PET) imaging agent called 64Cu-DOTA-pembrolizumab to see how well it works in determining treatment response for patients with stage IV…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT07619599
- Testing
- Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Glioma, Brain Metastases, Adult
Revision of the EORTC QLQ-BN20 Questionnaire
Despite the fact that use of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Brain Neoplasm (QLQ-BN20) has tremendously contributed to insight into the health-related quality…
- Trial name
- QLQBN20 (NCT04689321)
- Testing
- No intervention
- Where
- Netherlands
- Volunteers
- 135 people
- Sponsor
- Leiden University Medical Center
Breast Cancer, Brain Metastases
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
Sorafenib is a new type of anti-cancer drug. It belongs to a new class of medications known as tyrosine kinase inhibitors. Sorafenib is thought to work against cancer in many ways. It helps decrease blood supply to the tumor.
- Trial name
- NCT01724606
- Testing
- Whole Brain Radiotherapy (WBRT), Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.